![NCCN Recommends Molecular Testing for Pediatric Cancer Treatment](https://www.g2intelligence.com/wp-content/uploads/2022/07/July20-2022.News_.PediatricCancer-iStock-1800x1250-1-1080x675.jpg)
NCCN Recommends Molecular Testing for Pediatric Cancer Treatment
The new guidelines will likely prove highly influential with oncologists and payors.
The new guidelines will likely prove highly influential with oncologists and payors.
Here are the aspects of the proposed rule most likely to have an impact on labs and the businesses that own them.
New study shows that ctDNA liquid biopsy testing after stage II colon cancer may determine whether chemotherapy is required.
Team creates a mass spectrometry-based blood lipid test that, when combined with AI, identifies early signs of the disease.
A post-surgery liquid biopsy test capable of detecting ctDNA could eliminate the need for chemotherapy for some stage II cancer patients.